Trial Profile
The Vienna Prograf and Endothelial Progenitor Cell Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Tacrolimus (Primary) ; Ciclosporin
- Indications Renal transplant rejection
- Focus Biomarker; Pharmacodynamics
- Acronyms Vienna-PEP-Study
- 04 May 2013 New source identified and integrated (European Clinical Trials Database record: EudraCT2004-004209-98).
- 18 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Dec 2008 New trial record.